Sector News

Alexion Names David Hallal COO

September 18, 2014
Life sciences
(RTTNews) – Alexion Pharmaceuticals, Inc., whose durg Soliris treats two rare diseases, Wednesday said it is promoting David Hallal to the newly created position of chief operating officer.
 
Hallal, who joined the company in 2006, was previously its executive vice president and chief commercial officer. He led the launch of Soliris. Before Alexion, he was worked at Biogen Idec and Amgen.
 
The company also promoted two members of the management to executive vice president from vice president: Chief Human Resources Officer Clair Carmichael ; and General Counsel John Moriarty.
 
The company further said it appointed Edward Miller to the nearly created position of Senior Vice President and Chief Compliance Officer.
 

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach